Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAD/MAD study of INS-3001 in healthy adults and patients with moderate aortic valve stenosis
NL-OMON52051Phase 1Active, not recruiting
- Sponsor
- CSL Vifor
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INS-3001 in aortic stenosis (AS) and arterial calcification (4 arms), sponsored by CSL Vifor. Primary endpoint: Safety and tolerability. Started Nov 2021; status: active, not recruiting.
02
Drugs
INS-3001
03
Conditions
aortic stenosis (AS)arterial calcification
Beyond the preview
Go deeper on NL-OMON52051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52051.